Subanaesthetic intravenous ketamine has been shown to be as effective and not inferior to electroconvulsive therapy (ECT) for the treatment of non-psychotic, treatment-resistant depression.
Cybin Inc.
Psychedelics work by altering neural networks in our brains – this first-of-its-kind partnership between Clerkenwell Health and MYndspan will help understand this link definitively, and provide...
Two new drug candidates have been developed for the treatment of addiction and depression that have been modelled on the pharmacology of a traditional African psychoactive...
A new study has investigated whether psilocybin could be the key to restore ‘fear extinction’ and thus help treat post-traumatic stress disorder (PTSD).
A team of researchers have found that patterns of activity in the brain associated with nitrous oxide, ketamine and LSD overlap, suggesting a common underlying biology.
Cybin has announced the completion of dosing the last subject in Part B of its three-part CYB004-E Phase 1 trial evaluating intravenous (IV) DMT in healthy...
The first patient in Beckley Psytech’s trial investigating its patent-protected benzoate formulation of 5-MeO-DMT – BPL-003 – as a therapy for Treatment Resistant Depression (TRD) has...
Mind Medicine has presented positive topline data in Basel, Switzerland in April from a double-blind, investigator-initiated trial evaluating lysergide (LSD) in the treatment of Major Depressive...
Three promising studies featuring psilocybin, LSD and MDMA have shown signs of improved brain function.